Pharmaceuticals Trio Draw Buy Ratings Ahead of 2026 Catalysts
A trio of small-cap biotechs—X4 Pharmaceuticals, Immuneering, and Tango Therapeutics—are attracting new and renewed a...
What Affects Funding Timing
Identify the major factors influencing funding timing and practical steps to optimize speed from approval to disbursement.
16,493 articlesTrump Spent Hours at Walter Reed, Health Check Clear
Trump’s latest Walter Reed visit lasted over three hours, renewing questions about the president’s health and its imp...
Former Social Security Commissioner Proposes Taxing the Rich
A former social security commissioner argues for higher taxes on the wealthy to shore up Social Security. The idea so...
Social Security Cuts Could Cost Retirees Thousands Annually
A new SSA Trustees forecast projects a 22% cut to benefits by 2032 unless Congress acts. The impact could be about $5...
Exclusive: Translucent Raises $27M Series a AI-Native
Translucent closed a $27 million Series A to expand its AI-native healthcare finance platform, targeting improved rev...
Spacemobile Stock Just Crashed: A Practical Investor Guide
A sudden setback from a key launch partner has jolted AST SpaceMobile investors. This guide explains the causes, pote...
Venice’s $65M Raise Makes VVV Holders Reconsider Growth
Venice AI closes a $65 million Series A led by Dragonfly at a $1 billion valuation, funding growth with equity. The m...
This Energy Stock Could Skyrocket to $250 by 2040 Worldwide
Investing in tomorrow’s energy tech can feel risky. This article outlines how a compact, early-stage stock could grow...
Tsunami Seniors: Record Numbers Reshape Investing Landscape
As millions of Baby Boomers retire, a fundamental shift is underway for markets and investment strategies. This story...
Scrolling UBI: Deloitte’s Fastest-Growing Software Spotlight
A mobile platform that pays users to scroll is gaining momentum as it cracks Deloitte’s fastest-growing software rank...
OpenAI Capital Push: Open Should Strike While Hot Now
Private AI leaders OpenAI and Anthropic see valuations near $1 trillion as investors chase growth. A cooling IPO wind...
Palantir $11.2 Billion Revenue Backlog: Buy for 2026?
Palantir has a large revenue backlog, a major Army contract on the books, and ambitious growth guidance. This analysi...
Popular Topics
Fable
Smart Money Moves For Everyday Life
Investment Strategies In Energy Sector
Best Index Funds For Retirement
Investment Strategies
Untitled D6eff7ea
Crypto For Beginners
Best Dividend Etfs
Index
Innovative Skincare Clinical
Dutch Salary
Blue Owl
Budget
Ai Healthcare News
Penalty Vs No Penalty Depending On Lock Status